1-3 of 3
Nicholas Holzwart
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1 st FLOR Study

Rachel Koldej, Allison Barraclough, Sze Ting Lee, Huw Morgan, Nicholas Holzwart, Minu Koshy, Charmaine Smith, Geoffrey Chong, Michael Gilbertson, Colm Keane, Denise Lee, Leonid Churilov, David S. Ritchie, Eliza A. Hawkes
Journal: Blood
Blood (2024) 144 (Supplement 1): 4376.
https://doi.org/10.1182/blood-2024-199854
Published: 2024
Journal Articles

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Joanne Elizabeth Davis, Lina HH Le, Mandy Ludford-Menting, Nicholas Holzwart, Sasanka M Handunnetti, Constantine S. Tam, Mary Ann Anderson, David S. Ritchie, Rachel Koldej
Journal: Blood
Blood (2024) 144 (Supplement 1): 4384.
https://doi.org/10.1182/blood-2024-199866
Published: 2024
Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Clinical Trials & Observations
Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine Tam, Piers Blombery, David Westerman, David Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen Caldwell, Georgina Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel Koldej, Michael Dickinson
Journal: Blood
Blood (2024) 143 (8): 673–684.
https://doi.org/10.1182/blood.2023021306
Published: 2024
Includes: Supplemental data